Warm Autoimmune Hemolytic Anemia
Conditions
Brief summary
This is a Phase 2 non-randomized, open-label study to investigate the efficacy, safety and tolerability of RVT-1401 in patients with Warm Autoimmune Hemolytic Anemia.
Detailed description
This is a Phase 2, non-randomized, sequential, open-label study to investigate the safety, tolerability, PK, PD, and efficacy of RVT-1401 (680 mg/weekly and 340 mg/weekly) in patients with Warm Autoimmune Hemolytic Anemia that is worsening or refractory in spite of therapy with steroids and or immunosuppressants or worsening with steroid or immunosuppressant taper. Two cohorts of participants will be enrolled in a non-randomized sequential approach. Participants will be enrolled into Cohort 1 (680 mg/weekly) first followed by Cohort 2 (340 mg/weekly). Following the initial dose at the Baseline Visit (Week 1, Day 1), study visits will occur weekly throughout the treatment period. Following the final dose at Week 12, visits will occur weekly through Week 14 and then at Week 16 and Week 20. Safety, PK, PD, and clinical assessments will be collected throughout the study. Each participant will participate in the study for up to approximately 24 weeks: up to a 4-week screening period, a 12-week treatment period, and an 8-week follow up period.
Interventions
DRUGRVT-1401 680 mg/weekly
Non-randomized subjects will receive subcutaneous injection of 680 mg weekly for 12 weeks of RVT-1401
DRUGRVT-1401 340 mg/weekly
Non-randomized subjects will receive subcutaneous injection of 340 mg weekly for 12 weeks of RVT-1401
Sponsors
Immunovant Sciences GmbH
Study design
Allocation
NON_RANDOMIZED
Intervention model
SEQUENTIAL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Male or female ≥ 18 years of age. 2. Diagnosis of primary or secondary WAIHA as documented by a positive direct antiglobulin test (DAT) specific for anti-IgG alone or anti-IgG plus C3d. 3. Secondary WAIHA may only include Stage 0 chronic lymphocytic leukemia (CLL) in which separate treatment is not indicated, nor anticipated to require active management for the duration of the study. 4. Have failed or not tolerated at least one prior WAIHA treatment regimen as per local standards (e.g., steroids, rituximab, azathioprine, cyclophosphamide, cyclosporine, mycophenolate mofetil (MMF), danazol, or vincristine). Failure is defined as worsening or refractory disease despite steroids and or immunosuppressants. 5. Participants with splenectomy ≥3 months from Day 1 who are up to date on vaccinations (based on age and local guidance) are allowed. 6. At Screening and Baseline, subject's hemoglobin level must be \<10 g/dL and the subject must have documented symptoms related to anemia (e.g., weakness, dizziness, fatigue, shortness of breath, chest pain). 7. Subject's concurrent treatment for WAIHA may consist only of steroids (stable dose for at least two weeks prior to Day 1), immunosuppressant therapy (azathioprine, MMF, or cyclosporine) that has been at a stable dose for at least four weeks prior to Day 1, or erythropoietin (stable dose for at least 6 weeks prior to Day 1). \[Note: starting doses of WAIHA therapy must be maintained throughout the study except in the case of a rescue medication as per local standards for safety. Steroid taper down to 10 mg/day will be allowed for participants who achieve response for at least 2 weeks.\] 8. A female participant is eligible to participate if she is of: 1. Non-childbearing potential defined as pre-menopausal females with a documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy; hysteroscopic sterilization, or postmenopausal defined as 12 months of spontaneous amenorrhea. 2. Child-bearing potential and agrees to use one of the contraception methods listed in the protocol for an appropriate period of time (as determined by the product label or Principal Investigator) prior to the start of dosing to sufficiently minimize the risk of pregnancy at that point. Female participants must agree to use contraception until 90 days after the last dose of study treatment. 9. Male participants must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study treatment until 90 days after the last dose of study treatment. 10. Willing and capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form. Other, more specific inclusion criteria are defined in the protocol.
Exclusion criteria
1. Participants with other types of AIHA (e.g., cold antibody AIHA, cold agglutinin syndrome, mixed type AIHA, or paroxysmal cold hemoglobinuria). 2. Participants requiring more than 2 units of RBC per week in the 2 weeks prior to Screening and Baseline. 3. Use of rituximab, any monoclonal antibody for immunomodulation, or proteasome inhibitor, within the past 3 months prior to Screening. 4. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 60 days before Screening. 5. Total IgG level \<6 g/L (at Screening). 6. Absolute neutrophil count \<1000 cells/mm3(at Screening). Other, more specific
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Responders at Week 13 | Week 13 | Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks. |
| Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Up to Week 20 | AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score | Up to Week 13 | The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete. |
| Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale | Up to Week 13 | The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability. |
| Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score | Up to Week 20 | The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0). |
| Time to Response | Up to Week 13 | The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks). |
| Number of Participants With Presence of Anti-RVT 1401 Antibodies | Pre-dose on Weeks 1, 3, 5, 8, 13 and Week 20 | Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported |
| Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4) | Up to Week 20 | Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported. |
| Concentration of RVT-1401 Pre-dose | Pre-dose, Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12 and 13 post-dose | Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401. |
| Time to Achieving Hb Levels in the Normal Range | Up to Week 13 | Time to achieving Hb levels in the normal range was assessed. |
Countries
Israel, South Korea, Spain, Thailand, United Kingdom, United States
Participant flow
Pre-assignment details
A total of 11 participants were screened, of which 5 participants were enrolled and randomized into the study. The study was terminated early prior to completion of dosing all participants in Cohort 1 and prior to initiating Cohort 2, as efficacy and safety conclusions could not be drawn and Pharmacokinetics/Pharmacodynamics (PK/PD) data were limited, due to the small number of participants (n=5) enrolled in the study.
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1: RVT-1401 680 mg/Week Participants received RVT-1401 680 milligram (mg) subcutaneous (SC) injection weekly for 12 weeks. | 5 |
| Cohort 2: RVT-1401 340 mg/Week Participants were planned to receive RVT-1401 340 mg SC injection weekly for 12 weeks. | 0 |
| Total | 5 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 1 | 0 |
| Overall Study | Safety Concerns | 1 | 0 |
| Overall Study | Study Terminated by Sponsor | 1 | 0 |
Baseline characteristics
| Characteristic | Cohort 1: RVT-1401 680 mg/Week | Cohort 2: RVT-1401 340 mg/Week | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 4 Participants | 0 Participants | 4 Participants |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants | 0 Participants | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 5 Participants | 0 Participants | 5 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Asian | 4 Participants | 0 Participants | 4 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | 0 Participants | 1 Participants |
| Sex: Female, Male Female | 3 Participants | 0 Participants | 3 Participants |
| Sex: Female, Male Male | 2 Participants | 0 Participants | 2 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 5 | 0 / 0 |
| other Total, other adverse events | 5 / 5 | 0 / 0 |
| serious Total, serious adverse events | 1 / 5 | 0 / 0 |
Outcome results
Primary
Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death
AEs were defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Clinically significant changes determined by the Investigator such as vital signs, Electrocardiograms (ECGs), and clinical laboratory values were also reported as AEs. TEAEs were defined as AEs that either started on or after the date of the first dose of study drug. SAEs were defined as any untoward medical occurrence that, at any dose: resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect, or was an important medical event that may have jeopardized the participant or may have required medical or surgical intervention to prevent one of the other outcomes listed in the definition.
Time frame: Up to Week 20
Population: Safety Population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | TEAEs | 5 Participants |
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | SAEs | 1 Participants |
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Treatment-related AEs | 4 Participants |
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Any Treatment-emergent Adverse Event (TEAE), Serious AE (SAE), Treatment-related Adverse Event (AE), and Death | Deaths | 0 Participants |
Primary
Number of Responders at Week 13
Responders were defined as the participants with level of hemoglobin (Hb) \>=10 grams per deciliter (g/dL) with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous two weeks.
Time frame: Week 13
Population: Safety population: All participants who enrolled in the study and received at least 1 dose of study treatment. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Responders at Week 13 | 1 Participants |
Secondary
Concentration of RVT-1401 Pre-dose
Blood samples were planned to be collected at indicated time points to measure the concentration of RVT-1401 pre-dose (Ctrough) as an assessment of the pharmacokinetic (PK) RVT-1401.
Time frame: Pre-dose, Weeks 1, 2, 3, 4, 5, 6, 8, 10, 12 and 13 post-dose
Population: Safety Population. Data could not be calculated for Cohort 1 due to high proportion of non-quantifiable values (\>30 percent \[%\] of values were imputed). Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (GEOMETRIC_MEAN) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Concentration of RVT-1401 Pre-dose | NA Milligrams per liter |
Secondary
Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score
The EQ-5D-3L is a validated measurement of health-related quality of life. The scale consists of 2 components, the EQ-5D descriptive system and the EQ visual analogue scale (VAS). The descriptive system evaluates mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels: 1=no problems, 2=some problems, and 3=extreme problems; a lower score indicated better quality of life. The EQ VAS records the participant's self-rated health on a vertical visual analogue scale where the endpoints are labelled 'Best imaginable health state' (100) and 'Worst imaginable health state' (0).
Time frame: Up to Week 20
Population: Safety Population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Change in Euro Quality-5 Dimension-3 Level (EQ-5D-3L) Score | 4 Participants |
Secondary
Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score
The FACIT-F scale was a validated scale which measured the physical, emotional and social implications of fatigue, one of the key clinical manifestations of warm autoimmune hemolytic anemia. Scores ranged from 0-52, a higher score indicated a higher quality of life. A score of less than 30 indicated severe fatigue. The scale took approximately 5-10 minutes to complete.
Time frame: Up to Week 13
Population: Safety Population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Change in Functional Assessment of Chronic Illness Therapy-fatigue (FACIT-F) Score | 3 Participants |
Secondary
Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4)
Blood samples were collected at indicated time points for pharmacodynamic (PD) analysis of serum total IgG and IgG subclasses (1-4) concentrations. Participants with changes in levels of Total IgG and IgG Subclasses (1-4) is reported.
Time frame: Up to Week 20
Population: Safety Population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4) | Total IgG | 5 Participants |
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Change in Levels of Total Immunoglobulin (Ig)G and IgG Subclasses (1-4) | IgG Subclasses (1-4) | 5 Participants |
Secondary
Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale
The MRC Breathlessness scale is a questionnaire that consisted of 5 statements about perceived Breathlessness and the focus of the scale was to quantify the disability associated with breathlessness. Score ranged from Grade 0 (limited to no disability) to Grade 4 (severe disability); higher score indicated severe disability.
Time frame: Up to Week 13
Population: Safety Population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Change in Medical Research Council (MRC) Breathlessness Scale | 4 Participants |
Secondary
Number of Participants With Presence of Anti-RVT 1401 Antibodies
Blood samples were collected at indicated time points to determine presence of anti-RVT 1401 antibodies. Participants with presence of anti-RVT 1401 antibodies is reported
Time frame: Pre-dose on Weeks 1, 3, 5, 8, 13 and Week 20
Population: Safety population. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Number of Participants With Presence of Anti-RVT 1401 Antibodies | 0 Participants |
Secondary
Time to Achieving Hb Levels in the Normal Range
Time to achieving Hb levels in the normal range was assessed.
Time frame: Up to Week 13
Population: Safety Population. Only those participants with data available at the specified time points were analyzed. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Time to Achieving Hb Levels in the Normal Range | 5 Weeks |
Secondary
Time to Response
The time to response was defined as the amount of time to achieve response (Hb levels \>=10 g/dL with at least a \>=2 g/dL increase from Baseline without rescue therapy or blood transfusions in the previous 2 weeks).
Time frame: Up to Week 13
Population: Safety Population. Only those participants with data available at the specified time points were analyzed. Data was not collected for Cohort 2 due to early termination of the trial.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Cohort 1: RVT-1401 680 mg/Week | Time to Response | 3 Weeks |